4888 — Stella Pharma Cashflow Statement
0.000.00%
- ¥11bn
- ¥8bn
- ¥269m
Annual cashflow statement for Stella Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -959 | -656 | -764 | -776 | -761 |
Depreciation | |||||
Non-Cash Items | 7.4 | 12 | 7.85 | -1.29 | 6.58 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 9.32 | -160 | -359 | -85.5 | -157 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -914 | -773 | -1,081 | -828 | -877 |
Capital Expenditures | -41.2 | -22.4 | -46.3 | -29.3 | -11 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 1,599 | -0.42 | -304 | -0.596 | 1.97 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 1,558 | -22.9 | -351 | -29.9 | -9.01 |
Financing Cash Flow Items | -41 | -372 | 373 | 13.5 | 0.103 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -68.6 | -332 | 3,829 | 292 | 228 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 576 | -1,128 | 2,398 | -566 | -657 |